BoA Merrill Lynch advises on sale of Hugel US investment bank advised on three Korean mega deals in first half of 2022 alone
Translated by Ryu Ho-joung 공개 2022-05-09 07:58:37
이 기사는 2022년 05월 06일 08:14 thebell 에 표출된 기사입니다.
A consortium led by South Korea’s GS Holdings has completed the acquisition of Hugel from US private equity firm Bain Capital.The deal closed on Tuesday, eight months after the consortium agreed to buy a roughly 43.2% stake in the South Korean botox maker for about 1.7 trillion won ($1.34 billion) through a mix of new shares and hybrid debt in August last year.
Other investors in the consortium included Seoul-based private equity firm IMM Investment, Singapore-based healthcare-focused investment firm CBC Group and Abu Dhabi's sovereign wealth fund Mubadala.
Bain Capital is believed to have made big profits from the sale. The 1.7 trillion won price was almost twice what the firm paid for a 44.4% stake in the pharmaceutical company in 2017.
BoA Merrill Lynch advised Bain Capital. Including the Hugel sale, the US investment bank advised three mega deals in the South Korean mergers and acquisitions market this year alone: It worked with MBK Partners on the Doosan Machine Tools sale and advised KDB Investment on its sale of Daewoo Engineering & Construction. Both deals were valued at more than 2 trillion won.
BoA Merrill Lynch ranked second on the South Korean M&A league table for financial advisers compiled by the bell in 2021.
The Hugel sale was led by Chanhee Cho, managing director and head of BoA Merrill Lynch’s Seoul office. A Seoul National University graduate, Cho joined BoA Merrill Lynch in 2011 and was promoted to the current role in March last year.
The GS-led consortium’s deal for Hugel was subject to government approval because of botulinum toxin technology. The South Korean trade ministry gave the green light to the deal in December.
In February, GS Holdings and IMM Investment, the two South Korean investors in the consortium, signed the revised agreement to raise their stakes in Hugel, suggesting their strong commitment to growing the country’s leading botox maker.
Hugel, founded in 2001, made its Kosdaq debut in 2015. The pharmaceutical company offers botox, filler and cosmetics products, which represented 52%, 32% and 8% of its total revenue in 2020, respectively. (Reporting by Ha-na Suh)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- 폴라리스오피스, 클라이원트와 AI 문서 자동화 협업
- '텐스토렌트 맞손' 코아시아, 자회사 400억 투자 유치
- [Red & Blue]'변압기 관련주' 바이오스마트, 자회사 효과 '톡톡'
- [코스닥 자사주 점검]'양날의 검' 자사주, 변화의 바람 불까
- [thebell interview]"XR 서비스 3종 출시, B2C 플랫폼 구축 원년"
- SL에너지, 바이오중유 제조인허가 취득
- [동아-일동 'R&D 협업' 승부수]동아에스티, 일동 아이디언스에 250억 베팅 '2대주주' 등극
- [Company Watch]LG유플러스, 매출 대비 R&D 비율 첫 1%↑ 'AI 공략 강화'
- SC엔지니어링, M&A 매물 출회 가능성은
- 5월 기준금리 동결 유력…4분기로 밀리는 인하 시점